mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
bioRxiv
; 2023 Mar 23.
Article
em En
| MEDLINE
| ID: mdl-36993158
ABSTRACT
To prospectively determine whether brain tumors will respond to immune checkpoint inhibitors (ICIs), we developed a novel mRNA vaccine as a viral mimic to elucidate cytokine release from brain cancer cells in vitro. Our results indicate that cytokine signatures following mRNA challenge differ substantially from ICI responsive versus non-responsive murine tumors. These findings allow for creation of a diagnostic assay to quickly assess brain tumor immunogenicity, allowing for informed treatment with ICI or lack thereof in poorly immunogenic settings.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
BioRxiv
Ano de publicação:
2023
Tipo de documento:
Article